Q-linea AB (publ) (OMX: QLINEA) – Q-linea today announces that a university hospital in Belgium has received ethical approval to start a clinical impact study using ASTar.
The study will enroll 60 patients with Gram-negative bacteraemia over a six-month period and aims to explore the impact of ASTar results on time to optimal antibiotic therapy. The study is the first part of a broader research project investigating the benefits of using ASTar with therapeutic drug monitoring.
“Proving the clinical impact of ASTar is a key pillar of our clinical strategy, thus, we are delighted to announce that yet another study will soon be underway. This type of evaluation study is important for the commercial development but also to increase knowledge about benefits with rapid AST in general and ASTar in particular”, said Jonas Jarvius, CEO of Q-linea.